ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ADMA BIOLOGICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.07+0.39 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $2.55B
- P/E (TTM)
- 15.8
- Dividend yield
- –
Share price
−$3.29 (−22.91%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ADMA BIOLOGICS, INC. grew revenue 8.0% to $512.28M over the twelve months to Jun 30, 2026. Operating income rose 44.2% to $224.48M, moving the operating margin from 32.8% to 43.8%. Free cash flow was $116.47M, up 77.1% from a year earlier.
Revenue
$512.28M
+8.0% vs. a year earlier
Operating income
$224.48M
+44.2% vs. a year earlier
Free cash flow
$116.47M
+77.1% vs. a year earlier
EPS, diluted
$0.70
-17.6% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.55B
- P/E ratio
- 15.8
- Price to sales
- 4.98
- Price to book
- 6.25
- Dividend yield
- –
- Free cash flow yield
- 4.57%
Fundamentals
- Revenue
- $512.28M
- Net income
- $168.96M
- EPS, diluted
- $0.70
- Free cash flow
- $116.47M
- Book value per share
- $1.77
- Diluted shares
- 230M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$512.28M+8.0% YoY
Gross profit
$331.47M+31.9% YoY
Operating income
$224.48M+44.2% YoY
Net income
$168.96M-19.1% YoY
EPS, diluted
$0.70-17.6% YoY
Free cash flow
$116.47M+77.1% YoY
Reported periodTrailing twelve months